Wall Street brokerages forecast that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will report earnings per share of ($0.32) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Alpine Immune Sciences’ earnings. The lowest EPS estimate is ($0.58) and the highest is ($0.14). Alpine Immune Sciences reported earnings of ($0.30) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 6.7%. The business is expected to issue its next quarterly earnings report on Thursday, May 13th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.97) to ($0.62). For the next financial year, analysts anticipate that the firm will report earnings of ($1.21) per share, with EPS estimates ranging from ($2.73) to $1.03. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Wednesday, March 17th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. Alpine Immune Sciences had a negative return on equity of 80.38% and a negative net margin of 606.16%.
A number of analysts recently weighed in on ALPN shares. Oppenheimer reissued a “buy” rating and issued a $19.00 price objective on shares of Alpine Immune Sciences in a research report on Friday, March 19th. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 24th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.67.
In other Alpine Immune Sciences news, CEO Mitchell Gold sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 13th. The shares were sold at an average price of $10.07, for a total value of $100,700.00. Following the transaction, the chief executive officer now directly owns 260,039 shares in the company, valued at approximately $2,618,592.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 76.10% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of Alpine Immune Sciences by 18.0% in the 4th quarter. Renaissance Technologies LLC now owns 458,794 shares of the biotechnology company’s stock worth $5,781,000 after buying an additional 70,111 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Alpine Immune Sciences by 106.6% during the fourth quarter. Bank of New York Mellon Corp now owns 23,426 shares of the biotechnology company’s stock valued at $295,000 after purchasing an additional 12,088 shares in the last quarter. Avidity Partners Management LP boosted its stake in shares of Alpine Immune Sciences by 54.1% during the fourth quarter. Avidity Partners Management LP now owns 1,248,000 shares of the biotechnology company’s stock valued at $15,725,000 after purchasing an additional 438,000 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in Alpine Immune Sciences during the fourth quarter worth $1,137,000. Finally, Citigroup Inc. bought a new stake in Alpine Immune Sciences during the 4th quarter valued at $112,000. 52.86% of the stock is owned by institutional investors and hedge funds.
Shares of Alpine Immune Sciences stock traded up $0.41 during trading on Friday, hitting $11.91. The stock had a trading volume of 379 shares, compared to its average volume of 119,046. Alpine Immune Sciences has a 12 month low of $2.58 and a 12 month high of $16.37. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.98 and a quick ratio of 3.98. The firm’s fifty day simple moving average is $11.79 and its 200-day simple moving average is $11.22. The stock has a market cap of $284.43 million, a PE ratio of -8.41 and a beta of 1.72.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases.
Further Reading: What are some reasons analysts would give stocks a buy rating?
Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.